Alnylam Pharmaceuticals Inc (DUL F) stock market data APIs
€338.6062
0(0%)
as of December 30, 2025
Try our APIs with
free plan!
Alnylam Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Prev. Close
338.6062
Open
338.6062
High
338.6062
Low
338.6062
52 wk Range
198.7-423
Market Cap
44 641 M
P/E Ratio
1251.4814
Shares Outstanding
132 M
Revenue
3 210 M
EPS
-1.61
Beta
0.298
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Alnylam Pharmaceuticals Inc data using free add-ons & libraries
Get Alnylam Pharmaceuticals Inc Fundamental Data
Alnylam Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 3 210 M
- EBITDA: 321 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-08-03
- EPS/Forecast: -1.61
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Alnylam Pharmaceuticals Inc News
New
What PeptiDream (TSE:4587)'s New Oral IL-17 Program and RNAi Milestone Mean For Shareholders
PeptiDream Inc. recently announced that its second oral peptide therapeutic program, a dual IL-17A and IL-17F macrocyclic inhibitor for autoimmune diseases, has entered its clinical development portfo...
Here’s Why Alnylam Pharmaceuticals (ALNY) Surged in Q3
Brown Advisory, an investment management company, released its “Brown Advisory Mid-Cap Growth Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The strateg...
Alnylam’s Manufacturing Expansion and Extra-Hepatic RNAi Delivery Could Be A Game Changer For Alnylam Pharmaceuticals (ALNY)
In December 2025, Alnylam Pharmaceuticals announced a US$250 million expansion of its Norton, Massachusetts siRNA manufacturing facility and, together with PeptiDream, achieved a preclinical milestone...
Is It Too Late to Consider Alnylam After a 67.8% Surge in 2025?
If you are wondering whether Alnylam Pharmaceuticals at around $392 a share still offers value after a huge run, you are not alone. This is exactly the question we will unpack here. Despite a choppy r...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
